An Investigation of rhTPO With Different Frequencies in the Management of ITP
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The project was undertaking by Qilu Hospital of Shandong University and other well-known
hospitals in China. In order to study the efficacy and safety of different dose and frequency
Recombinant Human thrombopoietin in treating the primary immune thrombocytopenia (ITP)
Phase:
Phase 3
Details
Lead Sponsor:
Shandong University
Collaborators:
Shandong Provincial Hospital The First Affiliated Hospital of Dalian Medical University